PDEX
Pro-Dex, Inc.
PDEX's fundamentals are strong: revenue grew 13% and it turned 13% of its revenue into free cash flow. At 19x earnings, it's trading in line with its usual 18x. Analysts expect that strong growth to continue.
PDEX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
PDEX's revenue, profitability, cash flow and balance sheet are all currently healthy.
PDEX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $52.76 | -22% |
| Fair | 18x | $65.13 | -3.4% |
| Current | 19x | $67.42 | — |
| Forward | 21x | $67.42 | — |
| Expensive | 24x | $88.76 | +32% |
Historical ranges are pointers, not guarantees.
PDEX's PE is in its fair range at 19x. On analysts' estimates for next year's earnings, today's price would be 21x, in its expensive range.
PDEX Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for PDEX, with profitability improving.
PDEX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.18 | -13% |
| Q3 2026 | $3.64 | +9.6% |
| Q2 2026 | $4.12 | +54% |
| Q1 2026 | $3.59 | +29% |
| Q4 2025 | $3.37 | +69% |
| Q3 2025 | $3.32 | +118% |
| Q2 2025 | $2.67 | +345% |
| Q1 2025 | $2.78 | +415% |
| Q4 2024 | $1.99 | +180% |
PDEX's earnings per share have climbed steadily: $3.64 over the past year, up 9.6% from the year before, and higher year over year for nine quarters in a row.
PDEX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.6M | +11% |
| Q2 2026 | $20.4M | +17% |
| Q1 2026 | $19.9M | +15% |
| Q4 2025 | $18.7M | +11% |
| Q3 2025 | $18.5M | +24% |
| Q2 2025 | $17.5M | +16% |
| Q1 2025 | $17.4M | +22% |
| Q4 2024 | $16.8M | +33% |
PDEX's revenue has grown year over year for 13 quarters in a row: $21M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +0.3 points |
| Q2 2026 | 17% | +9.6 points |
| Q1 2026 | 16% | -5.4 points |
| Q4 2025 | 17% | +1.4 points |
| Q3 2025 | 17% | -3.4 points |
| Q2 2025 | 7.7% | -8 points |
| Q1 2025 | 21% | +5.4 points |
| Q4 2024 | 16% | +9.9 points |
PDEX's operating margin was 17% last quarter, about level with the same quarter a year ago.
PDEX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.1M | +178% |
| Q2 2026 | -$476K | -$303K |
| Q1 2026 | $1.5M | +165% |
| Q4 2025 | $3.5M | +$8.2M |
| Q3 2025 | $2.2M | +52% |
| Q2 2025 | -$173K | -117% |
| Q1 2025 | $574K | -86% |
| Q4 2024 | -$4.7M | -6194% |
PDEX's free cash flow has turned positive again: $11M over the past year, against −$2M the year before.
PDEX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -1.6K shares |
| 1 year | -0.7% | -23.4K shares |
| 3 years | -8.8% | -322K shares |
| 5 years | -17% | -660K shares |
PDEX has 3M diluted shares, down 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $600,000 |
| Q2 2026 | $600,000 |
| Q1 2026 | $601,000 |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $1.2M |
| Q3 2024 | $2.3M |
| Q2 2024 | $1.7M |
PDEX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.7x | Very low |
| Q1 2026 | 1.0x | Very low |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.4x | Healthy |
PDEX's net debt is less than a year of its operating earnings (EBITDA), down from 1.1 years a year ago.
PDEX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.7 | Neutral |
| Stochastic | 34.8 | Neutral |
PDEX's weekly RSI is 56 (neutral) and its Stochastic is 35 (neutral).
PDEX PE vs Healthcare Sector
| Metric | PDEX | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 26x | 28% below |
| PE % | 55 | 29 | 26 pts above |
PDEX is trading at 19x earnings, a 28% discount to the Healthcare sector's median of 26x.
PDEX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $63.4 | 6.3% above |
| 20 week MA | $63.6 | 6% above |
| 50 week MA | $54.9 | 23% above |
| 100 week MA | $48.6 | 39% above |
| 200 week MA | $34.6 | 95% above |
PDEX is in an uptrend: it's above all five of its weekly moving averages, and 95% above its 200-week average.
PDEX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.6 | $39.5 | +137% |
| 2021 | $39.5 | $23.6 | -40% |
| 2022 | $23.6 | $16.4 | -30% |
| 2023 | $16.4 | $17.5 | +6.8% |
| 2024 | $17.5 | $49.3 | +181% |
| 2025 | $49.3 | $39.5 | -20% |
| 2026 YTD | $39.5 | $67.4 | +71% |
PDEX's yearly returns have swung widely, from +181% in 2024 to −40% in 2021. It's up 71% so far in 2026.